-+ 0.00%
-+ 0.00%
-+ 0.00%

Leadman announced that the recombinant B-group meningococcal vaccine independently developed by Beijing Xiansheng Xiangrui Biological Products Co., Ltd., a holding subsidiary of the company, has initiated phase I clinical trials at the Hunan Provincial Center for Disease Prevention and Control to evaluate the safety, tolerability and initial immunogenicity of the vaccine in people aged 3 months and above. The company disclosed on August 6, 2026 that the product received the “Drug Clinical Trial Approval Notice” granted by the State Drug Administration. No vaccine against group B influenza has been approved for marketing in China.

Zhitongcaijing·11/17/2026 09:41:08
Listen to the news
Leadman announced that the recombinant B-group meningococcal vaccine independently developed by Beijing Xiansheng Xiangrui Biological Products Co., Ltd., a holding subsidiary of the company, has initiated phase I clinical trials at the Hunan Provincial Center for Disease Prevention and Control to evaluate the safety, tolerability and initial immunogenicity of the vaccine in people aged 3 months and above. The company disclosed on August 6, 2026 that the product received the “Drug Clinical Trial Approval Notice” granted by the State Drug Administration. No vaccine against group B influenza has been approved for marketing in China.